NASDAQ:LMNX - Luminex Stock Price, News, & Analysis

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Luminex declared a quarterly dividend on Wednesday, September 12th. Investors of record on Friday, September 21st will be paid a dividend of $0.06 per share on Friday, October 12th. This represents a $0.24 dividend on an annualized basis and a dividend yield of 0.81%. The ex-dividend date is Thursday, September 20th. View Luminex's Dividend History.

Luminex Co. (NASDAQ:LMNX) posted its quarterly earnings results on Monday, August, 6th. The medical instruments supplier reported $0.15 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.19 by $0.04. The medical instruments supplier had revenue of $79.60 million for the quarter, compared to the consensus estimate of $79.66 million. Luminex had a return on equity of 7.44% and a net margin of 10.57%. Luminex's quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.26 EPS. View Luminex's Earnings History.

Luminex is scheduled to release their next quarterly earnings announcement on Monday, October, 29th 2018. View Earnings Estimates for Luminex.

4 equities research analysts have issued 1-year target prices for Luminex's stock. Their forecasts range from $22.00 to $34.00. On average, they anticipate Luminex's stock price to reach $27.25 in the next year. This suggests that the stock has a possible downside of 7.8%. View Analyst Price Targets for Luminex.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Luminex.

Some companies that are related to Luminex include Penumbra (PEN), Globus Medical (GMED), Novocure (NVCR), Cantel Medical (CMD), NuVasive (NUVA), Merit Medical Systems (MMSI), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Glaukos (GKOS), Nevro (NVRO), Mazor Robotics (MZOR), Cardiovascular Systems (CSII), Cryolife (CRY), Tactile Systems Technology (TCMD) and AtriCure (ATRC).

Headlines about LMNX stock have been trending somewhat positive recently, according to Accern Sentiment. Accern ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Luminex earned a news and rumor sentiment score of 0.18 on Accern's scale. They also assigned news articles about the medical instruments supplier an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Luminex.

Luminex's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.83%), Renaissance Technologies LLC (4.47%), Dimensional Fund Advisors LP (4.39%), RGM Capital LLC (3.88%), Acadian Asset Management LLC (3.55%) and Northern Trust Corp (2.17%). Company insiders that own Luminex stock include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Harriss T Currie, Kevin M Mcnamara, Nachum Shamir, Robert J Cresci and Todd C Bennett. View Institutional Ownership Trends for Luminex.

LMNX stock was sold by a variety of institutional investors in the last quarter, including RGM Capital LLC, Renaissance Technologies LLC, Alambic Investment Management L.P., Russell Investments Group Ltd., DAFNA Capital Management LLC, Investment Management of Virginia LLC, Point72 Asset Management L.P. and Fisher Asset Management LLC. Company insiders that have sold Luminex company stock in the last year include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II and Todd C Bennett. View Insider Buying and Selling for Luminex.

LMNX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., WINTON GROUP Ltd, Acadian Asset Management LLC, Federated Investors Inc. PA, Spark Investment Management LLC, Schwab Charles Investment Management Inc., TD Asset Management Inc. and Citadel Advisors LLC. Company insiders that have bought Luminex stock in the last two years include Harriss T Currie and Nachum Shamir. View Insider Buying and Selling for Luminex.

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of LMNX stock can currently be purchased for approximately $29.57.

Luminex has a market capitalization of $1.35 billion and generates $306.57 million in revenue each year. The medical instruments supplier earns $29.42 million in net income (profit) each year or $0.91 on an earnings per share basis. Luminex employs 922 workers across the globe.

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]